Home > Research > Research Faculty
Search  
Research
Research Overview
Research Divisions
Research Faculty
Senior Investigator
Investigator
Associate Investigator
Adjunct Faculty
Clinical Research
Research Services
Technology Transfer At TGen
TGen DNA Sequencing Facility Data Retrieval

Patient Information
   Clinical Research
   Clinical Trials
   Faculty

Research Resources
   Technology Transfer
   Research Services

Education / Outreach

News

Help Support TGen

About TGen

Contact

TGen North

TGen Drug Development Services (TD2)
Research Faculty

Profile
Selected Publications
Melanoma Resources
Pollock, P.M., Cohen-Solal, K., Sood, R., Namkoong, J., Martino, J.J., Koganti, A., Zhu, H., Robbins, C., Makalowska, I., Shin, S.S., Marin, Y., Roberts, K.G., Yudt, L.M., Chen, A., Cheng, J., Incao, A., Pinkett, H.W., Graham,C.L., Dunn, K., Crespo-Carbone, S.M., Mackason, K.R., Ryan,K.B., Sinsimer, D., Goydos, J., Reuhl, K.R., Eckhaus, M., Meltzer, P.S., Pavan, W.J., Trent, J.M., Chen S.. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nature Genetics, 34, 108-12. 2003.

Pollock, P.M., Harper, U., Hansen, K., Yudt, L, Stark, M., Moses, T., Robbins, C., Hostetter, G., Wagner, U, Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Hayward, NK., Kallioniemi, O., Trent, J., Meltzer, P.. BRAF mutations in nevi implicate activation of MAPK pathway in initiation of melanocytic neoplasia. Nature Genetics, 33, 19-20. 2003.

Pollock, P.M., Walker, G.J., Glendening, J.M., Bloch, N.C., Fountain, J.W., Hayward, N.K.. Analysis of PTEN deletions and mutations in melanoma cell lines tumours. Melanoma Research, 12,565-75. 2002.

Pollock P.M., Welch J., Hayward N.K.. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res, 61, 1154-61. 2001.

Pollock, P.M., Spurr, N., Bishop, T., Newton-Bishop, J., Gruis, N., van der Velden, P.A., Goldstein, A.M., Tucker, M.A., Foulkes, W.D., Barnhill, R., Haber, D., Fountain, J., Hayward, N.K.. Haplotype analysis of 2 recurrent CDKN2A mutations in 10 melanoma families from three continents: Evidence for common founders and independent mutations. Human Mutation, 11,424-431. 1998.

Pollock, P.M., Castellano, M., Walters, M.K., Sparrow, L.E., Down, L.M., Gabrielli, B.G., Parsons, P.G., Hayward, N.K.. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Research, 57, 4868-4875. 1997.

Flores, J.F., Pollock, P.M., Walker, G.J., Glendening, M., Lin, A., Palmer, J.M., Walters, M.K., Hayward, N.K., Fountain, J.W.. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene, 15, 2999-3005. 1997.


Pam Pollock, Ph.D.
Adjunct Faculty
Cancer and Cell Biology Division





602-343-8815
602-343-8840
ppollock@tgen.org

TGen
445 N. Fifth Street
Phoenix, Arizona 85004



E-MAIL THIS ARTICLE

PRINT THIS PAGE


   Home | About TGen | Research | Clinical Research | Research Services | Education/Outreach

News | Help Support TGen | Contact | Careers
 

Copyright 2009, The Translational Genomics Research Institute (TGen)
445 N. Fifth Street, Phoenix, AZ 85004
phone 602.343.8400 toll free 1.800.642.4432